Cipla’s South African subsidiary Cipla Medpro and mAbxience have entered into an agreement to supply oncology and respiratory-related biosimilars – included on the World Health Organization’s model list of essential medicines – to South Africa.
Commenting on the partnership, Paul Miller, CEO of Cipla South Africa, said “Cipla is built on the foundation of ensuring affordable and accessible drugs to patients in need
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?